Literature DB >> 1929879

Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.

H Schätzl1, H R Gelderblom, H Nitschko, K von der Helm.   

Abstract

Newly developed substrate analogue peptidomimetics are able to inhibit the human immunodeficiency virus, HIV-1 proteinase at nanomolar concentration. In HIV infected cell culture they exhibit antiviral activity. We have analyzed the non-infectious HIV particles produced in chronically HIV infected cell culture in presence of one of these inhibitors. The total production of virus particles was not substantially reduced in drug treated cultures, compared to non-inhibited control cultures, but the infectivity of these virus particles was reduced about 100 fold. The processing of gag and gag-pol protein precursor was inhibited; only borderline activity of reverse transcriptase (RT) could be detected in these particles and they contained nonprocessed gag precursor protein. Thin section electron microscopy of inhibitor-treated, HIV-infected cells revealed reduced viral cytopathogenicity and both inhibition of particle assembly and incomplete maturation of the particles formed. The HIV particles produced in the presence of the proteinase inhibitor were studded with envelope glycoprotein knobs and often comprised multiple budding regions, but were morphologically immature.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929879     DOI: 10.1007/bf01310950

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  18 in total

1.  Properties of avian retrovirus particles defective in viral protease.

Authors:  L Stewart; G Schatz; V M Vogt
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A.

Authors:  K von der Helm; L Gürtler; J Eberle; F Deinhardt
Journal:  FEBS Lett       Date:  1989-04-24       Impact factor: 4.124

3.  An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.

Authors:  P Ashorn; T J McQuade; S Thaisrivongs; A G Tomasselli; W G Tarpley; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

Authors:  S Seelmeier; H Schmidt; V Turk; K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

5.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

Authors:  J Erickson; D J Neidhart; J VanDrie; D J Kempf; X C Wang; D W Norbeck; J J Plattner; J W Rittenhouse; M Turon; N Wideburg
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

6.  Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.

Authors:  H G Kräusslich; H Schneider; G Zybarth; C A Carter; E Wimmer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Rational design of peptide-based HIV proteinase inhibitors.

Authors:  N A Roberts; J A Martin; D Kinchington; A V Broadhurst; J C Craig; I B Duncan; S A Galpin; B K Handa; J Kay; A Kröhn
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

Review 8.  Morphogenesis and morphology of HIV. Structure-function relations.

Authors:  H R Gelderblom; M Ozel; G Pauli
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.

Authors:  H R Gelderblom; E H Hausmann; M Ozel; G Pauli; M A Koch
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

10.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

Authors:  C Peng; B K Ho; T W Chang; N T Chang
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

View more
  19 in total

1.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Authors:  S Alireza Rabi; Gregory M Laird; Christine M Durand; Sarah Laskey; Liang Shan; Justin R Bailey; Stanley Chioma; Richard D Moore; Robert F Siliciano
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

3.  Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

Authors:  K Wiegers; G Rutter; H Kottler; U Tessmer; H Hohenberg; H G Kräusslich
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

5.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Authors:  M Markowitz; H Mo; D J Kempf; D W Norbeck; T N Bhat; J W Erickson; D D Ho
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 6.  The gag proteins of human immunodeficiency virus type 1: mechanisms of virus assembly and possibilities for interference.

Authors:  S Modrow; B Kattenbeck; A von Poblotzki; M Niedrig; R Wagner; H Wolf
Journal:  Med Microbiol Immunol       Date:  1994-09       Impact factor: 3.402

7.  DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.

Authors:  M M Rayner; B C Cordova; R P Meade; P E Aldrich; P K Jadhav; Y Ru; P Y Lam
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Authors:  Ping Zhu; Elena Chertova; Julian Bess; Jeffrey D Lifson; Larry O Arthur; Jun Liu; Kenneth A Taylor; Kenneth H Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

9.  Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.

Authors:  D A Davis; K Yusa; L A Gillim; F M Newcomb; H Mitsuya; R Yarchoan
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.

Authors:  H G Göttlinger; T Dorfman; E A Cohen; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.